Home » Stocks » ANIP

ANI Pharmaceuticals, Inc. (ANIP)

Stock Price: $30.34 USD 0.84 (2.85%)
Updated Mar 8, 2021 4:00 PM EST - Market closed
Market Cap 364.57M
Revenue (ttm) 199.19M
Net Income (ttm) -23.75M
Shares Out 12.00M
EPS (ttm) -1.98
PE Ratio n/a
Forward PE 8.31
Dividend n/a
Dividend Yield n/a
Trading Day March 8
Last Price $30.34
Previous Close $29.50
Change ($) 0.84
Change (%) 2.85%
Day's Open 29.89
Day's Range 29.26 - 30.56
Day's Volume 43,701
52-Week Range 23.55 - 52.22

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 6 days ago

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 2 weeks ago

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI“ or the “Company“) (Nasdaq: ANIP) today announced that ANI's Board of Directors granted non-qualified inducement stock options...

Business Wire - 2 weeks ago

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the addition of three key pharmaceutical executives: Christopher K. Mutz as ...

Business Wire - 2 weeks ago

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2020 financia...

Business Wire - 1 month ago

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Prazosin HCl Capsules USP, 1mg and 2mg, following the U.S. Foo...

Business Wire - 2 months ago

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) approval and the launch of Aminocapr...

Zacks Investment Research - 3 months ago

Let's see if ANI Pharmaceuticals (ANIP) stock is a good choice for value-oriented investors right now from multiple angles.

Seeking Alpha - 4 months ago

ANI Pharmaceuticals, Inc.'s (ANIP) CEO Nikhil Lalwani on Q3 2020 Results - Earnings Call Transcript

GuruFocus - 4 months ago

According to the GuruFocus All-in-One Screener as of Nov. 5, the following medical technology stocks are popular among gurus.

Other stocks mentioned: SRGA, VNDA, PETS, SRDX
Business Wire - 4 months ago

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced business highlights and financial results for the three and nine months ende...

Business Wire - 4 months ago

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2020 financial results on Th...

Zacks Investment Research - 4 months ago

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 5 months ago

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc.

Seeking Alpha - 6 months ago

ANI Pharmaceuticals, Inc. (ANIP) CEO Patrick Walsh on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 7 months ago

ANI (ANIP) delivered earnings and revenue surprises of -2.82% and 6.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 7 months ago

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc.

Business Wire - 7 months ago

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc.

Business Wire - 7 months ago

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc.

Business Wire - 7 months ago

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc.

Zacks Investment Research - 7 months ago

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 8 months ago

BAUDETTE, Minn., July 6, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the acquisition of Fluconazole Tablets USP, 50mg, 100mg, 150mg, and 200mg from a ...

Seeking Alpha - 8 months ago

ANI Pharmaceuticals: Significantly Undervalued

The Motley Fool - 9 months ago

Here's why a new initiative by the FDA to reduce drug prices is great for patients but should raise the alarm among pharmaceutical investors.

Other stocks mentioned: LCI, MYL, PFE, TARO, TEVA
Seeking Alpha - 9 months ago

ANI Pharmaceuticals, Inc. (ANIP) CEO Arthur Przybyl on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

ANI (ANIP) delivered earnings and revenue surprises of 16.85% and 0.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to th...

The Motley Fool - 10 months ago

A small-cap pharmaceuticals company may hold the solution to a nearly 100,000% drug price hike.

Seeking Alpha - 1 year ago

ANI Pharmaceuticals, Inc. (ANIP) CEO Arthur Przybyl on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

ANI (ANIP) delivered earnings and revenue surprises of -8.47% and -6.32%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Why ANI Pharmaceuticals Considers Corticotropin Gel Its Blockbuster Drug

Zacks Investment Research - 1 year ago

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

Other stocks mentioned: IMMU, MRTX, PTCT
Zacks Investment Research - 1 year ago

ANI Pharmaceuticals could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Zacks Investment Research - 1 year ago

ANI (ANIP) delivered earnings and revenue surprises of -16.89% and -10.25%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Other stocks mentioned: AIZ, AVA, EXPI, OPRA
Seeking Alpha - 1 year ago

ANI Pharmaceuticals, Inc. (ANIP) CEO Arthur Przybyl on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

ANI (ANIP) delivered earnings and revenue surprises of 11.63% and -2.24%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Successful sNDA for cortrophin addresses a $1 billion infantile spasms market in dire need of generic competition.

Zacks Investment Research - 1 year ago

ANI (ANIP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seeking Alpha - 1 year ago

ANI Pharmaceuticals Inc. (ANIP) CEO Arthur Przybyl on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

ANI Pharmaceuticals (ANIP) closed at $70.24 in the latest trading session, marking a -1.04% move from the prior day.

Zacks Investment Research - 1 year ago

ANI Pharmaceuticals (ANIP) will provide updates on product launches, when it releases first-quarter 2019 results.

Zacks Investment Research - 1 year ago

The U.S. economy grew 3.2% in the first quarter of 2019, primarily on two typically volatile components - inventories and trade.

Other stocks mentioned: ACIW, BBBY, DXPE, FL
Zacks Investment Research - 1 year ago

In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $68.88, marking a -0.17% move from the previous day.

Zacks Investment Research - 1 year ago

Is (ANIP) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 1 year ago

ANI (ANIP) could produce exceptional returns because of its solid growth attributes.

Zacks Investment Research - 1 year ago

In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $69.44, marking a +1.71% move from the previous day.

Zacks Investment Research - 1 year ago

Coherus (CHRS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Other stocks mentioned: CHRS

About ANIP

ANI Pharmaceuticals, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company offers pharmaceuticals for the treatment of breast cancer, hypertension, ventricular arrhythmias, stage D2 metastatic carcinoma of the prostate, depression, diarrhea, infections, vasomotor symptoms of menopause, pain caused by osteoarthritis ... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
2001
CEO
Patrick Walsh
Employees
338
Stock Exchange
NASDAQ
Ticker Symbol
ANIP
Full Company Profile

Financial Performance

In 2019, ANIP's revenue was $206.55 million, an increase of 2.47% compared to the previous year's $201.58 million. Earnings were $6.09 million, a decrease of -60.67%.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for ANIP stock is "Buy." The 12-month stock price forecast is 38.33, which is an increase of 26.33% from the latest price.

Price Target
$38.33
(26.33% upside)
Analyst Consensus: Buy